Carregant...
Natalizumab in Crohn’s Disease: Results from a US tertiary IBD center
BACKGROUND AND AIMS: Natalizumab is an efficacious agent for induction and maintenance of remission in Crohn’s disease (CD) patients who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center. M...
Guardat en:
| Publicat a: | Inflamm Bowel Dis |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4779049/ https://ncbi.nlm.nih.gov/pubmed/23429449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0b013e31827eea78 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|